U.S. Markets open in 1 hr 28 mins

CLASS ACTION UPDATE for NERV, KNDI and TCDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / February 2, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

NERV Shareholders Click Here: https://www.zlk.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?prid=12609&wire=1
KNDI Shareholders Click Here: https://www.zlk.com/pslra-1/kandi-technologies-group-inc-loss-submission-form?prid=12609&wire=1
TCDA Shareholders Click Here: https://www.zlk.com/pslra-1/tricida-inc-loss-submission-form?prid=12609&wire=1

* ADDITIONAL INFORMATION BELOW *

Minerva Neurosciences, Inc. (NASDAQ:NERV)

NERV Lawsuit on behalf of: investors who purchased May 15, 2017 - November 30, 2020
Lead Plaintiff Deadline : February 8, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?prid=12609&wire=1

According to the filed complaint, during the class period, Minerva Neurosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Kandi Technologies Group, Inc. (NASDAQ:KNDI)

KNDI Lawsuit on behalf of: investors who purchased March 15, 2019 - November 27, 2020
Lead Plaintiff Deadline : February 9, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/kandi-technologies-group-inc-loss-submission-form?prid=12609&wire=1

According to the filed complaint, during the class period, Kandi Technologies Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Kandi artificially inflated its reported revenues through undisclosed related party transactions, or otherwise had relationships with key customers that indicated those customers did not have an arms length relationship with Kandi; (ii) the majority of Kandi's sales in the past year had been to undisclosed related parties and/or parties with such a close relationship and history with Kandi that it cast doubt on the arms-length nature of their relationship; (iii) all the foregoing, once revealed, was foreseeably likely to cast doubt on the validity of Kandi's reported revenues and, in turn, have a foreseeable negative impact on the Company's reputation and valuation; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Tricida, Inc. (NASDAQ:TCDA)

TCDA Lawsuit on behalf of: investors who purchased September 4, 2019 - October 28, 2020
Lead Plaintiff Deadline : March 8, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tricida-inc-loss-submission-form?prid=12609&wire=1

According to the filed complaint, during the class period, Tricida, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Tricida's NDA for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/627289/CLASS-ACTION-UPDATE-for-NERV-KNDI-and-TCDA-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders